Synopsis
Synopsis
0
VMF
0
FDF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. (e)-n-(6,6-dimethyl-2-heptenynyl)-n-methyl-1-naphthalenementhamin Hydrochloride
2. Da 5505
3. Lamisil
4. Sf 86 327
5. Sf 86-327
6. Sf 86327
7. Sf-86-327
8. Sf86327
9. Tdt 067
10. Tdt-067
11. Tdt067
12. Terbinafine
13. Terbinafine, (z)-
14. Terbinafine, (z)-isomer
1. Terbinafine Hcl
2. 78628-80-5
3. Lamisil At
4. (e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine Hydrochloride
5. Bramazil
6. Bramizil
7. Muzonal
8. Terbina
9. Terbine
10. Terbinafina
11. Terbinafinum
12. Zabel
13. Nsc-759113
14. Cpd000469152
15. Terbinafine (as Hydrochloride)
16. Chebi:77614
17. 012c11zu6g
18. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylamine Hydrochloride
19. Trans-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthylmethylamine Hydrochloride
20. 78628-80-5 (hcl)
21. Lamisil Krem
22. Trans-n-(6,6-dimethyl-2-hepten-4-ylyl)-n-methyl-1-naphthylmethylamine Hydrochloride
23. Terbinafinum [latin]
24. Terbinafina [spanish]
25. Athletes Foot
26. Mycova
27. (e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine;hydrochloride
28. [(2e)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)(naphthalen-1-ylmethyl)amine Hydrochloride
29. N-[(2e)-6,6-dimethyl-2-hepten-4-yn-1-yl]-n-methyl-1-naphthalenemethanamine Hydrochloride
30. Sf 86-327 Hydrochloride
31. Smr000469152
32. N,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine Hydrochloride
33. Drg-0286
34. Terbinafine (hydrochloride)
35. Terbisil
36. Afogan
37. Terbifoam
38. Innonyx
39. Unii-012c11zu6g
40. Lamisil (tn)
41. Terbinafine Hydrochloride [usp:jan]
42. Mfcd00145430
43. Terbinafine,hydrochloride
44. Ec 616-640-4
45. Terbinafine Monohydrochloride
46. Schembl36793
47. Schembl36795
48. Mls001066620
49. Mls001304037
50. Mls001401424
51. Terbinafine Hydrochloride,(s)
52. Chembl1200832
53. Dtxsid90229223
54. Htu-520
55. Pharmakon1600-01505392
56. Terbinafine Hydrochloride, >=98%
57. Terbinafine Hydrochloride (lamisil)
58. Ac-761
59. Nsc759113
60. S2557
61. Terbinafine Hydrochloride [mi]
62. Akos015844100
63. Akos025149216
64. Terbinafine Hydrochloride (jp17/usp)
65. Bcp9000834
66. Ccg-101026
67. Cs-1123
68. Ks-1289
69. Nc00276
70. Nsc 759113
71. Terbinafine Hydrochloride [jan]
72. Terbinafine Hydrochloride [mart.]
73. Terbinafine Hydrochloride [vandf]
74. 1-naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-, (e)-, Monohydrochloride
75. 1-naphthalenemethanamine, N-[(2e)-6,6-dimethyl-2-hepten-4-yn-1-yl]-n-methyl-, Hydrochloride (1:1)
76. Bt164461
77. Hy-17395
78. Ls-14899
79. Sf-86327
80. Terbinafine Hydrochloride [usp-rs]
81. Terbinafine Hydrochloride [who-dd]
82. Nm-100060
83. B2047
84. D2049
85. Sw197656-2
86. D02219
87. Terbinafine Hydrochloride [ep Monograph]
88. Terbinafine Hydrochloride [orange Book]
89. Terbinafine Hydrochloride [usp Monograph]
90. 628t805
91. A839463
92. Q-201790
93. Q27147212
94. Terbinafine Hydrochloride, Antibiotic For Culture Media Use Only
95. Terbinafine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
96. (2e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine Hydrochloride
97. (2e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine Hydrochloride (1:1)
98. (2e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-aminium Chloride
99. (2e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine Hydrochloride
100. (e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-aminehydrochloride
101. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethanamine Hydrochloride
102. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthylmethylamine Hydrochloride
103. [(e)-6,6-dimethylhept-2-en-4-ynyl]-methyl-(naphthalen-1-ylmethyl)azanium;chloride
104. Terbinafine For System Suitability, European Pharmacopoeia (ep) Reference Standard
105. Terbinafine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
106. Terbinafine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
107. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylamine, Hydrochloride
108. 1-naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-, (e)-, Hydrochloride
Molecular Weight | 327.9 g/mol |
---|---|
Molecular Formula | C21H26ClN |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 5 |
Exact Mass | 327.1753775 g/mol |
Monoisotopic Mass | 327.1753775 g/mol |
Topological Polar Surface Area | 3.2 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 428 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Lamisil |
Drug Label | Lamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C21H26... |
Active Ingredient | Terbinafine hydrochloride |
Dosage Form | Tablet; Cream; Granule |
Route | Oral; Topical |
Strength | eq 187.5mg base/packet; 1%; eq 250mg base; eq 125mg base/packet |
Market Status | Over the Counter; Prescription |
Company | Novartis |
2 of 6 | |
---|---|
Drug Name | Lamisil at |
Active Ingredient | Terbinafine hydrochloride; Terbinafine |
Dosage Form | Spray; Gel; Solution |
Route | Topical |
Strength | 1% |
Market Status | Over the Counter |
Company | Novartis |
3 of 6 | |
---|---|
Drug Name | Terbinafine hydrochloride |
PubMed Health | Terbinafine |
Drug Classes | Antifungal |
Drug Label | Terbinafine hydrochloride tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empiri... |
Active Ingredient | Terbinafine hydrochloride |
Dosage Form | Tablet; Cream |
Route | oral; Oral; Topical |
Strength | 1%; eq 250mg base |
Market Status | Tentative Approval; Over the Counter; Prescription |
Company | Wockhardt; Harris Pharm; Breckenridge Pharm; Teva; Apotex; Aurobindo Pharma; Taro; Andrx Pharm; Invagen Pharms; Cipla; Glenmark Generics; Dr Reddys Labs; Orchid Hlthcare; Mylan |
4 of 6 | |
---|---|
Drug Name | Lamisil |
Drug Label | Lamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C21H26... |
Active Ingredient | Terbinafine hydrochloride |
Dosage Form | Tablet; Cream; Granule |
Route | Oral; Topical |
Strength | eq 187.5mg base/packet; 1%; eq 250mg base; eq 125mg base/packet |
Market Status | Over the Counter; Prescription |
Company | Novartis |
5 of 6 | |
---|---|
Drug Name | Lamisil at |
Active Ingredient | Terbinafine hydrochloride; Terbinafine |
Dosage Form | Spray; Gel; Solution |
Route | Topical |
Strength | 1% |
Market Status | Over the Counter |
Company | Novartis |
6 of 6 | |
---|---|
Drug Name | Terbinafine hydrochloride |
PubMed Health | Terbinafine |
Drug Classes | Antifungal |
Drug Label | Terbinafine hydrochloride tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empiri... |
Active Ingredient | Terbinafine hydrochloride |
Dosage Form | Tablet; Cream |
Route | oral; Oral; Topical |
Strength | 1%; eq 250mg base |
Market Status | Tentative Approval; Over the Counter; Prescription |
Company | Wockhardt; Harris Pharm; Breckenridge Pharm; Teva; Apotex; Aurobindo Pharma; Taro; Andrx Pharm; Invagen Pharms; Cipla; Glenmark Generics; Dr Reddys Labs; Orchid Hlthcare; Mylan |
Treatment of onychomycosis
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15887
Submission : 2002-03-06
Status : Active
Type : II
Certificate Number : R1-CEP 2009-008 - Rev 02
Issue Date : 2018-01-19
Type : Chemical
Substance Number : 1734
Status : Valid
Date of Issue : 2022-06-06
Valid Till : 2025-06-25
Written Confirmation Number : WC-0035a
Address of the Firm :
NDC Package Code : 55111-024
Start Marketing Date : 2002-03-06
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Sungwoo Chemical Co., Ltd.
Registration Date : 2014-07-07
Registration Number : 20050831-49-A-99-09(5)
Manufacturer Name : Dr.Reddy's Laboratories Ltd
Manufacturer Address : Unit-III, Plot No. 116, Sri Venkateswara Co-operative Industrial Estate, IDA Bollaram, Jinnaram Mandal, Sangareddy District, Telangana, India
Shuangda Pharmaceutical has a world-class first-class production line, having GMP, FDA and other regulatory certifications.
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Date of Issue : 2023-02-14
Valid Till : 2024-02-26
Written Confirmation Number : WC-0494
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17790
Submission : 2004-10-29
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-05-15
Pay. Date : 2017-03-23
DMF Number : 30940
Submission : 2017-03-23
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint in the Phase 2b trial (BBTAF202) in patients with onychomycosis, showing superiority over placebo (vehicle) with a high level of statistical significance.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: BB2603
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Lead Product(s) : Terbinafine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis
Details : BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint in the Phase 2b trial (BBTAF202) in patients with onychomycosis, showing superiority over placebo (vehicle) with a high level of statistical significance.
Brand Name : BB2603
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2023
Details:
MOB-015 (terbinafine) is an in-house developed topical formulation, which is investigated for the treatment of onychomycosis and Topline results are expected in January 2025.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: MOB-015
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Lead Product(s) : Terbinafine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Moberg Pharma has Completed Enrollment to the Phase 3 Study for MOB-015 in North America
Details : MOB-015 (terbinafine) is an in-house developed topical formulation, which is investigated for the treatment of onychomycosis and Topline results are expected in January 2025.
Brand Name : MOB-015
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2023
Details:
Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 (terbinafine hydrochloride) in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: MOB-015
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Padagis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 04, 2022
Lead Product(s) : Terbinafine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Padagis
Deal Size : Undisclosed
Deal Type : Agreement
Moberg Pharma and Padagis Sign Agreement For MOB-015 in Israel
Details : Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 (terbinafine hydrochloride) in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.
Brand Name : MOB-015
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 04, 2022
Details:
With the IND in place the company has initiated a Phase IIb international, multicentre double-blinded study.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2020
Lead Product(s) : Terbinafine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : With the IND in place the company has initiated a Phase IIb international, multicentre double-blinded study.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 28, 2020
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?